Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults
- PMID: 30202941
- PMCID: PMC6376080
- DOI: 10.1093/cid/ciy774
Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults
Abstract
Clinical trials for Staphylococcus aureus bloodstream infections (SAB) are broadly grouped into 2 categories: registrational trials intended to support regulatory approval of antibiotics for the treatment of SAB and strategy trials intended to inform clinicians on the best treatment options for SAB among existing antibiotics. Both types of SAB trials are urgently needed but have been limited by cost, complexity, and regulatory uncertainty. Here, we review key SAB trial design considerations for investigators, sponsors, and regulators.
Keywords: Staphylococcus aureus; bacteremia; clinical trials.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
References
-
- US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. US Department of Health and Human Services, Food and Drug Administration, 2013. Available at: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidan....
-
- Pertel PE, Bernardo P, Fogarty C, et al. . Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46:1142–51. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical